Page 184 - Read Online

Page 10 of 11 Paranaguá-Vezozzo et al. Hepatoma Res 2018;4:11 I http://dx.doi.org/10.20517/2394-5079.2018.17

5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
6. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.
7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
8. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum
C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in
compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
9. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004;127:S62-71.
10. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila J. Effectiveness of AFP and ultrasound tests on hepatocellular
carcinoma mortality in HCV-infected patients in the USA. Gut 2011;60:992-7.
11. Mittal S, Kanwal F, Ying J, Chung R, Sada YH, Temple S, Davila JA, El-Serag HB. Effectiveness of surveillance for hepatocellular
carcinoma in clinical practice: a United States cohort. J Hepatol 2016;65:1148-54.
12. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical
practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
13. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the
treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.
14. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T,
Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines
on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
15. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage
hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
16. Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA; Brazilian HCC Study Group. Clinical and epidemiological aspects of
hepatocellular carcinoma in Brazil. Clinics (Sao Paulo) 2010;65:1285-90.
17. Paranaguá-Vezozzo DC, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ.
Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Ann Hepatol 2014;13:386-93.
18. Paranagua-Vezozzo DC, Matielo CE, Chagas AL, Kikuchi LO, Mello ES, Alves VA, Ono-Nita SK, Carrilho FJ. Incidence of
hepatocellular carcinoma in cirrhotic patients in Sao Paulo, Brazil. Hepatology 2006;44:A504-5.
19. van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KM, Klümpen HJ, Jansen PL, IJzermans JN, van Oijen MG,
Siersema PD, van Erpecum KJ. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large
cohort in the Netherlands. J Hepatol 2015;63:1156-63.
20. Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, Baytarian M, Fox R, Hunt K, Pedrosa M, Pocha C, Valderrama
A, Kaplan DE. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology
2017;65:864-74.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
22. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
23. Burnham KP, Anderson DR. Model selection and multi-model inference: a practical information-theoretic approach. New York: Springer-
Verlag; 2002.
24. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology
2004;127:S35-50.
25. Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Statist Assoc 1983;78:316-31.
26. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L. Prospective analysis of risk
factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7.
27. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag
JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in
hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
28. Bruix J, Llovet JM. HCC surveillance: who is the target population? Hepatology 2003;37:507-9.
29. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme
of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
30. Messori A, Badiani B, Trippoli S. Achieving sustained virological response in hepatitis C reduces the long-term risk of hepatocellular
carcinoma: an updated meta-analysis employing relative and absolute outcome measures. Clin Drug Investig 2015;35:843-50.
31. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A
systematic review and critical analysis. Ann Intern Med 2003;139:46-50.
32. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of
America. J Gastroenterol Hepatol 2001;16:553-9.
33. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
34. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular
carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014;146:1249-55.
35. Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected
patients. Clin Gastroenterol Hepatol 2012;10:428-33.
36. Bird TG, Dimitropoulou P, Turner RM, Jenks SJ, Cusack P, Hey S, Blunsum A, Kelly S, Sturgeon C, Hayes PC, Bird SM. Alpha-
fetoprotein detection of hepatocellular carcinoma leads to a standardized analysis of dynamic AFP to improve screening based detection.
PLoS One 2016;11:e0156801.
37. Lu CY, Lin KY, Tien MT, Wu CT, Uen YH, Tseng TL. Frequent DNA methylation of MiR-129-2 and its potential clinical implication in